Auro Laboratories Stock Screener | Share Price & Fundamental Analysis
AUROLAB
Pharmaceuticals
Share Price BSE
₹255.75
▲
3.55 (1.41%)
As of April 28, 2026, the Auro Laboratories share price (BSE: AUROLAB) is ₹255.75, up 1.41% from the previous close, with shares trading between ₹240.60 and ₹257.00, and a 52-week range of ₹179.25–₹302.05.
Browse AUROLAB complete financial to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Auro Laboratories Market Cap
₹158.29 Cr.
AUROLAB P/E Ratio (TTM)
84.75
Auro Laboratories P/B Ratio
3.63
EPS (TTM)
₹2.95
Dividend Yield
-
Debt to Equity
0.81
AUROLAB 52 Week High
₹302.05
Auro Laboratories 52 Week Low
₹179.25
Operating Margin
1.00%
Profit Margin
-
AUROLAB Revenue (TTM)
₹3.00
EBITDA
-
Net Income
-
Total Assets
₹99.00
Total Equity
₹43.00
Auro Laboratories Share Price History - Stock Screener Chart
Screen AUROLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Auro Laboratories Company Profile - Fundamental Screener
Screen Auro Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for AUROLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE292C01011
Auro Laboratories Balance Sheet Screener
Screen AUROLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 99 | 86 | 56 | 55 | 42 | 32 | 34 | 30 | 27 | 26 |
| Current Assets | 22 | 31 | 36 | 38 | 28 | 18 | 19 | 16 | 14 | 12 |
| Fixed Assets | 21 | 22 | 13 | 14 | 14 | 14 | 15 | 13 | 13 | 9 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 35 | 20 | 4 | 3 | 4 | 5 | 10 | 11 | 11 | 7 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 43 | 42 | 34 | 32 | 29 | 22 | 17 | 13 | 9 | 9 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 37 | 36 | 28 | 25 | 22 | 15 | 11 | 7 | 3 | 2 |
Auro Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Auro Laboratories income statement and profit fundamentals.
Analyze AUROLAB quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Auro Laboratories share price evaluation.
| Item | 2025-Jun | 2025-Sept | 2024-Jun | 2024-Sept |
|---|---|---|---|---|
| Revenue | 3 | 10 | 6 | 3 |
| Expenses | 3 | 7 | 4 | 2 |
| EBITDA | 0 | 3 | 2 | 1 |
| Operating Profit % | 1.00% | 27.00% | 23.00% | 23.00% |
| Depreciation | 0 | 1 | 0 | 0 |
| Interest | 0 | 1 | 0 | 0 |
| Profit Before Tax | 0 | 2 | 1 | 1 |
| Tax | 0 | 1 | 0 | 0 |
| Net Profit | 0 | 1 | 1 | 0 |
| EPS | -0.17 | 1.15 | 1.21 | 0.57 |
Auro Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen AUROLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 6 | 19 | 3 | -7 | 13 | 9 | 7 | 6 | 7 | 8 |
| Investing Activities | -25 | -39 | -5 | -5 | -4 | -2 | -3 | -3 | -2 | -2 |
| Financing Activities | 18 | 19 | -8 | 10 | -1 | -6 | -2 | -2 | -4 | -5 |
| Net Cash Flow | -1 | -1 | -10 | -2 | 9 | 2 | 2 | 1 | 1 | 0 |
Auro Laboratories Shareholding Pattern Screener
See Auro Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Auro Laboratories promoter holding and ownership changes for AUROLAB on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 52.18% | 52.18% | 52.18% | 52.18% | 52.18% | 52.15% | 52.15% | 52.15% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 36.28% | 36.57% | 36.42% | 36.35% | 36.26% | 35.03% | 35.33% | 35.42% |
| Other Holding | 11.54% | 11.25% | 11.40% | 11.47% | 11.56% | 12.81% | 12.52% | 12.43% |
| Shareholder Count | 8,405 | 9,102 | 8,916 | 8,860 | 8,640 | 9,441 | 9,335 | 9,266 |
Auro Laboratories Share Dividend Screener - Share Yield Analysis
Check Auro Laboratories dividend history with payout and yield data.
View Auro Laboratories dividend details including ex-dates and amounts for AUROLAB stock.
Auro Laboratories Stock Index Membership
See which indices include Auro Laboratories stock.
Check AUROLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Auro Laboratories Market Events Screener - Corporate Actions
Get Auro Laboratories corporate actions including splits, bonuses, and buybacks.
Check Auro Laboratories stock events that may affect AUROLAB share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -2.73% | ||
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 22.56% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -2.46% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -3.89% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 0.06% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -2.41% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | -0.22% |
| 2024-06-28 | 2024-06-28 | Annual General Meeting | NA | -13.67% |
Auro Laboratories Competitors Screener - Peer Comparison
Screen AUROLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 415,925 | 35.49 | 54,729 | 9.71% | 10,980 | 54.07 |
| Divis Laboratories | 171,944 | 68.10 | 9,712 | 18.67% | 2,191 | 68.17 |
| Torrent Pharmaceuticals | 142,817 | 61.31 | 11,539 | 6.99% | 1,911 | 54.09 |
| Dr Reddys Laboratories | 111,383 | 19.89 | 33,741 | 16.73% | 5,725 | 64.26 |
| Cipla | 106,401 | 23.07 | 28,410 | 7.12% | 5,291 | 64.71 |
| Lupin | 106,240 | 22.48 | 22,910 | 13.74% | 3,306 | 53.12 |
| Zydus Life Science | 94,551 | 18.56 | 23,511 | 18.55% | 4,615 | 58.75 |
| Mankind Pharma | 93,653 | 51.90 | 12,744 | 20.90% | 2,007 | 67.97 |
| Aurobindo Pharma | 82,282 | 23.56 | 32,346 | 9.43% | 3,484 | 67.39 |
| Glenmark Pharmaceuticals | 65,615 | 60.89 | 13,436 | 6.18% | 1,047 | 65.50 |
Auro Laboratories Company Announcements - News Screener
Screen AUROLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-14 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-02-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-05 | Financial Results For The Quarter Ended December 31 2025 | - |
| 2026-02-05 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-01-28 | Board Meeting Intimation for Unaudited Financial Results For Quarter Ended December 31 2025. | - |
| 2026-01-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-26 | Closure of Trading Window | - |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-12 | Grant Of Certificate Of Good Manufacturing Practices From World Health Organisation (WHQ"). | - |
| 2025-11-12 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | - |
| 2025-11-12 | Board Meeting Outcome for Outcome Of The Board Meeting Dated November 12 2025 | - |
| 2025-11-06 | Board Meeting Intimation for Unaudited Financial Results Of The Company For Quarter And Half Year Ended September 30 2025. | - |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-09-29 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-09-26 | Closure of Trading Window | - |
| 2025-09-25 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-09-03 | Regulation 36(1)(B) Of SEBI (LODR) Regulations | - |